CAR-T cell therapy after stem cell transplant for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether giving BCMA-targeting CAR-T cells after a stem cell transplant can help treat newly diagnosed multiple myeloma. It is for people who are healthy enough for both procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have been diagnosed with multiple myeloma and are eligible for a stem cell transplant
- Your liver function is within safe limits (ALT and AST less than 3 times normal)
- You are generally active and able to care for yourself (KPS score over 50%)
- You do not have serious heart, liver, or other organ problems
- You are willing to undergo both a stem cell transplant and CAR-T cell therapy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining CAR-T cell therapy with a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to see if this approach can help when other treatments have failed.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
This trial tests whether a newer immune treatment (BCMA CAR-T) works better than a stem cell transplant for people with multiple myeloma who are able to have a transplant. Both treatments aim to kill myeloma cells, but CAR-T uses your own engineered immune cells.
This study tests a new CAR-T cell therapy that targets a protein called BCMA on myeloma cells. It is for patients with newly diagnosed multiple myeloma who cannot have a standard stem cell transplant. The therapy is a one-time infusion of your own immune cells that are modified to attack the cancer.
This trial compares a new immune cell therapy (CAR-T) with a standard stem cell transplant to see which works better for people newly diagnosed with multiple myeloma. It aims to find a more effective treatment option.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.